Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.

Kristin M Zimmerman SavillJasmina IvanovaParisa AsgarisabetAngelica FalkensteinAlexandrina BalaneanAlexander NiyazovJoanne C RyanJonathan KishAjeet GajraReshma L Mahtani

Published in: The oncologist (2023)

Overall, talazoparib clinical outcomes in this real-world population are consistent with findings from EMBRACA.

Keyphrases

dna repair
young adults
insulin resistance
newly diagnosed
weight loss
childhood cancer